PPARG and metabolic dysfunction-associated steatotic liver disease: Concomitantly, SREBP-1c is also found in high levels in patients with NAFLD, acting with PPARgamma to favor lipogenesis and accumulation of triglycerides in hepatic tissue [3], [47].